Research Paper Volume 13, Issue 7 pp 9522—9541

EGB761 ameliorates chronic cerebral hypoperfusion-induced cognitive dysfunction and synaptic plasticity impairment

EGB761 could improve hippocampus-dependent spatial cognition dysfunction after CCH in rats in MWM and NOR test. The spatial cognitive function were examined by MWM. The latency finding the platform (A), crossing times (B) and staying time (C) in platform areas were recorded and analyzed the learning abilities. The all rats’ swimming velocity was recorded to evaluate the moving abilities (D). The short-term memory was assessed by recording and analyzing latency finding the platform (E), crossing times (F) and staying time in platform areas (G) after removing the platform. NOR test was carried out for further evaluated the rats’ spatial cognition. The staying time on familiar and novel object were recorded. Then the exploration ratio (H, I), and exploration recognition index were counted and analyzed (J). Con: the sham group (n=14); 2VO: the group receiving CCH by 2-vessel occlusion (n=12); 2VO+EGB761: the group receiving 2-vessel occlusion and EGB761 treatment (n=14); EGB761: the sham group receiving EGB761 treatment (n=13). *, PP

Figure 1. EGB761 could improve hippocampus-dependent spatial cognition dysfunction after CCH in rats in MWM and NOR test. The spatial cognitive function were examined by MWM. The latency finding the platform (A), crossing times (B) and staying time (C) in platform areas were recorded and analyzed the learning abilities. The all rats’ swimming velocity was recorded to evaluate the moving abilities (D). The short-term memory was assessed by recording and analyzing latency finding the platform (E), crossing times (F) and staying time in platform areas (G) after removing the platform. NOR test was carried out for further evaluated the rats’ spatial cognition. The staying time on familiar and novel object were recorded. Then the exploration ratio (H, I), and exploration recognition index were counted and analyzed (J). Con: the sham group (n=14); 2VO: the group receiving CCH by 2-vessel occlusion (n=12); 2VO+EGB761: the group receiving 2-vessel occlusion and EGB761 treatment (n=14); EGB761: the sham group receiving EGB761 treatment (n=13). *, P<0.05; **, P<0.01.